Literature DB >> 26509432

A retrospective analysis of false-positive infectious screening results in blood donors.

Michelle T Vo1, Roberta Bruhn2, Zhanna Kaidarova2, Brian S Custer2,3, Edward L Murphy2,3, Evan M Bloch2,3.   

Abstract

BACKGROUND: False-positive infectious transfusion screening results remain a challenge with continued loss of both donors and blood products. We sought to identify associations between donor demographic characteristics (age, race, sex, education, first-time donor status) and testing false positive for viruses during routine blood donation screening. In addition the study assessed the prevalence of high-risk behaviors in false-positive donors. STUDY DESIGN AND METHODS: Blood Systems, Inc. donors with allogeneic donations between January 1, 2011, and December 31, 2012, were compared in a case-control study. Those with a false-positive donation for one of four viruses (human immunodeficiency virus [HIV], human T-lymphotropic virus [HTLV], hepatitis B virus [HBV], and hepatitis C virus [HCV]) were included as cases. Those with negative test results were controls. For a subset of cases, infectious risk factors were evaluated.
RESULTS: Black race and Hispanic ethnicity were associated with HCV and HTLV false-positive results. Male sex and lower education were associated with HCV false positivity, and age 25 to 44 was associated with HTLV false positivity. First-time donors were more likely to be HCV false positive although less likely to be HBV and HTLV false positive. No significant associations between donor demographics and HIV false positivity were observed. A questionnaire for false-positive donors showed low levels of high-risk behaviors.
CONCLUSION: Demographic associations with HCV and HTLV false-positive results overlap with those of true infection. While true infection is unlikely given current testing algorithms and risk factor evaluation, the findings suggest nonrandom association. Further investigation into biologic mechanisms is warranted.
© 2015 AABB.

Entities:  

Mesh:

Year:  2015        PMID: 26509432      PMCID: PMC4828031          DOI: 10.1111/trf.13381

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  20 in total

1.  Reduced frequency of blood donors with false-positive HIV-1 and -2 antibody EIA reactivity after elution of low-affinity nonspecific natural antibodies.

Authors:  Marlene Bouillon; Eric Aubin; Chantal Roberge; Renée Bazin; Réal Lemieux
Journal:  Transfusion       Date:  2002-08       Impact factor: 3.157

2.  Improved efficiency of national HIV, HCV, and HTLV antibody testing algorithms based on sequential screening immunoassays.

Authors:  Clive R Seed; Angelo R Margaritis; Wayne V Bolton; Philip Kiely; Susan Parker; Lisa Piscitelli
Journal:  Transfusion       Date:  2003-02       Impact factor: 3.157

3.  Impact of changes in viral marker screening assays.

Authors:  Usha K Sharma; Susan L Stramer; David J Wright; Simone A Glynn; Sigurd Hermansen; George B Schreiber; Steven H Kleinman; Michael P Busch
Journal:  Transfusion       Date:  2003-02       Impact factor: 3.157

Review 4.  Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells.

Authors:  Zhao-Hua Zhou; Athanasios G Tzioufas; Abner Louis Notkins
Journal:  J Autoimmun       Date:  2007-09-20       Impact factor: 7.094

Review 5.  Estimating the cost of blood: past, present, and future directions.

Authors:  Aryeh Shander; Axel Hofmann; Hans Gombotz; Oliver M Theusinger; Donat R Spahn
Journal:  Best Pract Res Clin Anaesthesiol       Date:  2007-06

Review 6.  Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations.

Authors:  Shimian Zou; Susan L Stramer; Roger Y Dodd
Journal:  Transfus Med Rev       Date:  2011-08-25

7.  Human T-lymphotropic virus antibody screening of blood donors: rates of false-positive results and evaluation of a potential donor reentry algorithm.

Authors:  Susan L Stramer; Edward P Notari; Shimian Zou; David E Krysztof; Jaye P Brodsky; Gary E Tegtmeier; Roger Y Dodd
Journal:  Transfusion       Date:  2010-10-07       Impact factor: 3.157

8.  Limited effectiveness of donor deferral registries for transfusion-transmitted disease markers.

Authors:  Ritchard Cable; Fatemeh Musavi; Edward Notari; Shimian Zou
Journal:  Transfusion       Date:  2007-09-24       Impact factor: 3.157

9.  Seroprevalence and demographic determinants of human T-lymphotropic virus type 1 and 2 infections among first-time blood donors--United States, 2000-2009.

Authors:  Yun Brenda Chang; Zhanna Kaidarova; Daniel Hindes; Marjorie Bravo; Nancy Kiely; Hany Kamel; Denise Dubay; Barbara Hoose; Edward L Murphy
Journal:  J Infect Dis       Date:  2013-09-24       Impact factor: 5.226

10.  Reduction of the HIV seroconversion window period and false positive rate by using ADVIA Centaur HIV antigen/antibody combo assay.

Authors:  Kyunghoon Lee; Hyung-Doo Park; Eun-Suk Kang
Journal:  Ann Lab Med       Date:  2013-10-17       Impact factor: 3.464

View more
  2 in total

1.  Alternative hepatitis B virus DNA confirmatory algorithm identified occult hepatitis B virus infection in Chinese blood donors with non-discriminatory nucleic acid testing.

Authors:  Xuelian Deng; Xiaohan Guo; Tingting Li; Syria Laperche; Liang Zang; Daniel Candotti
Journal:  Blood Transfus       Date:  2020-12-17       Impact factor: 3.443

2.  COVID-19 in a human T-cell lymphotropic virus type-1 carrier.

Authors:  Takatoshi Enomoto; Takayuki Shiroyama; Haruhiko Hirata; Saori Amiya; Yuichi Adachi; Takayuki Niitsu; Yoshimi Noda; Reina Hara; Kiyoharu Fukushima; Yasuhiko Suga; Kotaro Miyake; Shohei Koyama; Kota Iwahori; Izumi Nagatomo; Natsuko Tokuhira; Akinori Uchiyama; Yoshito Takeda; Atsushi Kumanogoh
Journal:  Clin Case Rep       Date:  2022-02-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.